anti-steap2/exatecan antibody-drug conjugate azd0516
Generic: Anti-STEAP2/Exatecan Antibody-drug Conjugate AZD0516
anti-steap2/exatecan antibody-drug conjugate azd0516: 1 clinical trial tracked.
anti-steap2/exatecan antibody-drug conjugate azd0516 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-steap2/exatecan antibody-drug conjugate azd0516, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer
Primary endpoint: Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs)
InterventionalRandomizedopen177 targetStarted 2025-10Completion 2029-0150 sites · Brazil, China, France, Italy…AstraZeneca